12.05.24 -- One Percent Of A Hundred People's Efforts

An adverse side effect for some drugs is suicidal ideation and behavior (SIB). Investigating SIB in animal studies represents the closest approximation to human SIB, yet the FDA Modernization Act 3.0 obligates us to reduce unnecessary animal testing. Let's examine this with data-driven research.

By founding their latest venture, Abpro, Ian and Eugene Chan are using their synergistic skillsets in business and medicine to rapidly generate antibodies that treat cancer and autoimmune diseases.

Uncover the implications of the BIOSECURE Act and how US-based pharmaceutical companies and CDMOs are adapting to the new legislative landscape in order to remain competitive.

Market dynamics will continue to favor engaging with CDMO partners who have the capabilities and experience to manage short-term needs while anticipating and planning for long-term requirements.

Explore how, much like a fingerprint, each B-cell possesses a unique identity, and how deciphering this code can unlock a wealth of possibilities in antibody development, immunotherapy, and beyond.

ADCs have proven to be highly effective in cancer treatment, but their manufacturing poses challenges. Learn how a CDMO partner can help bring these treatments to patients safely and efficiently.

Vial fogging is a common phenomenon observed in lyophilized biologic drug products. Here, we present two case studies that explore factors contributing to vial fogging and inform vial selection decisions.

Whether you’re at the discovery stage or thinking about commercial production, gain useful insights on expression formats from transient transfection, through stable pools to stable clones.

Discover a CHO AOF panel that provides rapid detection of relevant adventitious viral contaminants in bulk harvest material, and explore data showing equivalent sensitivity to the in vitro assay.

Manufacturing RNA-containing LNPs demands specialized expertise. Explore some of the challenges of RNA-LNP drug manufacturing and the advantages of outsourcing RNA-LNP formulations.

Depending on the protein or peptide of interest for your therapeutic and manufacturing goals, there are a number of different approaches that can prove advantageous. Learn more about these various methods.

Consider this approach for process characterization to produce a monoclonal antibody, specifically at the drug substance biomanufacturing step, to improve efficiency and effectiveness.

Leverage our integrated CRO and CDMO services for the development and manufacturing of complex biologics, bioconjugates, and ADCs, ensuring high-quality products and data packages.

Gain valuable insights into our mammalian development services, manufacturing solutions, upcoming capacity availability, as well as updates on expansion timelines for external clients.

With over 30 years of expertise in biological processing and a proven track record in the chemical and biotechnological industries, we provide customers with a "one-stop-shop" service.

Our scientists offer insights into physicochemical and structural properties, including post-translational modifications, through a range of assays.

Partner with us for full-service ADC development and production, from feasibility to GMP manufacturing, with industry-leading standards and flexible capacities.